SEC Company Response from Passage BIO, Inc. (PASG) (CIK 0001787297) (PASG) — Jan 19, 2021
Passage BIO, Inc. (PASG) (CIK 0001787297)
Date: Jan. 19, 2021 · CIK: 0001787297 · Accession: 0001104659-21-005393
AI Filing Summary & Sentiment
File numbers found in text: 333-252213
Show Raw Text
CORRESP
1
filename1.htm
Passage Bio, Inc.
2001 Market Street, 28th Floor
Philadelphia, PA 19103
January 19, 2021
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, DC 20549
Attention:
Tim Buchmiller
Re:
Passage Bio, Inc. Registration Statement on Form S-1 (File No. 333-252213) originally filed January 19, 2021.
Requested Date: January 21, 2021
Requested Time: 4:30 PM Eastern Time
Ladies and Gentlemen:
Passage Bio, Inc.
(the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action
to declare the above-captioned Registration Statements on Form S-1 effective at the “Requested Date” and “Requested
Time” set forth above or as soon thereafter as practicable.
The Registrant hereby
authorizes Robert A. Freedman or Ryan Mitteness, both of whom are attorneys with the Registrant’s outside legal counsel,
Fenwick & West LLP, to orally modify or withdraw this request for acceleration.
The Registrant requests
that it be notified of such effectiveness by a telephone call to Mr. Freedman at (650) 335-7292 or, in his absence, Mr. Mitteness
at (206)-389-4533.
* * *
Sincerely,
passage bio,
inc.
By: /s/
Bruce Goldsmith
Bruce Goldsmith, Ph.D.
Chief
Executive Officer
cc:
Richard S. Morris, Chief Financial Officer
Passage
Bio, Inc.
Ryan
Mitteness, Esq.
Robert
A. Freedman, Esq.
Fenwick
& West LLP